KetamineOne Capital has announced that the company will change its name to Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc.
Wellbeing will continue to trade under the stock symbol ‘MEDI’ on the NEO Exchange, under the stock symbol ‘KONEF’ on the OTCQB Venture Market and under the symbol ‘MY0’ on the Frankfurt Stock Exchange.
“We are excited to announce our new name and reveal our updated branding that is better aligned with our multidisciplinary approach, which encompasses mental and physical health through the pursuit of a variety of traditional and novel digital therapeutics,” said Adam Deffett, interim CEO of Wellbeing.
He added: “Wellbeing Digital Sciences is a name that acknowledges each one of our three core pillars: clinic-based treatments, contract research, and health technology.”
READ: Ketamine One becomes exclusive provider of ketamine treatment to Victoria Wellness
Deffett said that the company’s mission continues to be the implementation of an innovative and bespoke healthcare offering to underserved populations, such as military veterans and first responders.
The company also reaffirmed that its pursuits continue to be centered around the mission and vision statements which include bringing a technology-first approach to psychedelic therapies and drug development; operating a network of clinics that support treatments, future research, clinical trials, and the integration of digital therapeutics; and advancing the integration wearable technology and artificial intelligence-powered technology partnerships into each patient’s experience.
With its name change, Wellbeing has launched a new website at www.wellbeingdigital.co.
The new website prominently features the strength and clarity of the new Wellbeing brand, with content that includes more information about the company, the market potential, mental health, a patient portal, investor materials, and news.
Wellbeing Digital Sciences is an evidence-based healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics, and contract research. Its mission is supported by a network of North American clinics that provide ketamine-assisted therapies and other types of treatment to patients as well as through a contract research organization that offers clinical trials services to clients pursuing drug development.
Contact Ritika at ritika@proactiveinvestors.com